Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the pancreas * Metastatic disease * Unidimensionally measurable disease outside of the pancreas * At least 1 lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan * Must have received 1, and only 1, prior gemcitabine-containing regimen for metastatic disease unless disease has recurred within 6 months after treatment with neoadjuvant or adjuvant gemcitabine-containing therapy * No brain metastases PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-1 Life expectancy * Not specified Hematopoietic * WBC at least 3,000/mm\^3 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Hemoglobin at least 9.0 g/dL (transfusion allowed) * No bleeding diathesis or coagulopathy Hepatic * Bilirubin no greater than upper limit of normal (ULN) * AST and ALT no greater than 1.5 times ULN * INR no greater than ULN * PTT no greater than ULN Renal * Creatinine no greater than 2.0 mg/dL * No clinically significant renal impairment * Urine protein:creatinine ratio ≥ 1.0 Cardiovascular * No prior myocardial infarction * No prior stroke * No clinically significant cardiovascular disease * No uncontrolled hypertension (i.e., blood pressure greater than 160/110 mm Hg on medication) * No unstable angina * No New York Heart Association class II-IV congestive heart failure * No serious cardiac dysrhythmia requiring medication * No peripheral vascular disease Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No history or evidence of CNS disease (e.g, primary brain tumor or seizures not controlled with standard medical therapy) * No other medical condition that would preclude study participation * No psychiatric condition that would preclude study participation * No other prior or concurrent malignancy that would preclude study participation * No significant traumatic injury within the past 28 days * No serious, nonhealing wound, ulcer, or bone fracture PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent prophylactic granulocyte or platelet growth factors Chemotherapy * See Disease Characteristics * More than 4 weeks since prior chemotherapy Endocrine therapy * Not specified Radiotherapy * At least 4 weeks since prior radiotherapy Surgery * More than 7 days since prior fine needle aspirations or core biopsies * More than 28 days since prior surgery (except closed biopsy or access port placement) * More than 28 days since prior open biopsy * No concurrent surgery Other * More than 4 weeks since prior experimental drug study participation * More than 4 weeks since prior investigational drugs * No other concurrent experimental drug study participation